Timothy S Lewis

This inventor holds 9 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Seattle Genetics, Inc., Seagen Inc.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy S Lewis. Retrieved from https://idiyas.com/inventor/timothy-s-lewis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Kenmore, WA (US) (2017 - 2022)
Bothell, WA (US) (2016 - 2023)

Company Filing History:

5 out of 132

Seattle Genetics, Inc.

Years Active: 2016-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12496353 - SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY (2025-12-16),

2. 11617798 - Anti-CD228 antibodies and antibody-drug conjugates (2023-04-04),

3. 11607460 - Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway (2023-03-21),

4. 11351269 - Anti-NTB-A antibodies and related compositions and methods (2022-06-07),

5. 10722592 - CD48 antibodies and conjugates thereof (2020-07-28),

6. 10435468 - Anti-NTB-A antibodies and related compositions and methods (2019-10-08),

7. 10201615 - Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway (2019-02-12),

8. 9708404 - Anti-NTB-A antibodies and related compositions and methods (2017-07-18),

9. 9272052 - Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway (2016-03-01),

Title: The Innovative Contributions of Timothy S. Lewis

Introduction

Timothy S. Lewis is a prominent inventor based in Bothell, WA (US), known for his significant contributions to the field of cancer treatment. With a total of 9 patents, Lewis has made remarkable strides in developing novel therapeutic approaches.

Latest Patents

Among his latest patents are the development of anti-CD228 antibodies and antibody-drug conjugates. These innovations provide novel methods for using such antibodies and conjugates to treat cancer effectively. Another notable patent focuses on the synergistic effects between auristatin-based antibody-drug conjugates and inhibitors of the PI3K-AKT-mTOR pathway. This invention outlines methods for treating cancer by administering an auristatin-based antibody-drug conjugate alongside an inhibitor of the PI3K-AKT-mTOR pathway.

Career Highlights

Throughout his career, Timothy S. Lewis has worked with leading companies in the biotechnology sector, including Seattle Genetics, Inc. and Seagen Inc. His work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations

Lewis has collaborated with notable professionals in his field, including Che-Leung Law and Julie A. McEarchern. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Timothy S. Lewis continues to be a driving force in cancer research and treatment through his innovative patents and collaborations. His work exemplifies the impact of dedicated inventors in the medical field.

Profile summary based on public USPTO records.